Nephronomics
Nephronomics is a precision-medicine biotech, joint-ventured with Fresenius Medical Care, that uses machine learning over a >42,000-patient whole-genome renal disease database to discover and develop targeted therapies for cardio-kidney-metabolic and primary renal diseases for pharmaceutical partners.
- Company typePrivate
- Founded2023
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Nephronomics does
Nephronomics is a precision-medicine biotechnology company developing targeted therapies for cardio-kidney-metabolic (CKM) and primary renal diseases. The company is structured as a joint venture between Mechanica Partners and Fresenius Medical Care, giving it exclusive access to the Nephronomics Atlas — described as the world's most robust clinical and genomics renal disease database — consisting of matched whole genome sequencing and longitudinal medical records from more than 42,000 consented patients across U.S. dialysis clinics. The Atlas is built on Fresenius's My Reason IRB-approved research program, which has assembled biospecimens and phenotypic data from over 35,000 patients.
The company's core offering is a vertically integrated platform that layers proprietary machine learning and computational biology tools on top of the Atlas. The platform analyzes unstructured text from electronic medical records, multi-omics data, and imaging data across the cohort to surface novel genome-phenome associations, identify clinically relevant subtypes within the CKM spectrum, predict disease progression and survival fitness, and stratify patients by cardio-renal profiles for partner programs. Scientific advisors and founders cover nephrology, human genomics, and therapeutics discovery.
Nephronomics operates as an enterprise B2B business serving pharmaceutical and biotechnology companies. The company generates revenue through co-development programs, data and AI platform licensing, and precision-medicine services for patient stratification and target discovery, while also building internal therapeutic programs. In April 2026, CerraCap Ventures made a strategic investment (undisclosed terms) to support the platform and pipeline expansion.
Nephronomics firmographics
Firmographics- Name
- Nephronomics
- Legal name
- Nephronomics
- Website
- https://nephronomics.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nephronomics is a precision-medicine biotech, joint-ventured with Fresenius Medical Care, that uses machine learning over a >42,000-patient whole-genome renal disease database to discover and develop targeted therapies for cardio-kidney-metabolic and primary renal diseases for pharmaceutical partners.
- Ownership category
- akta.pro rank
Nephronomics industry classification
Industry- Product category
- Precision Medicine Platform
- NAICS
- Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
Keywords
Where Nephronomics is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Nephronomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Partnerships and Co-development: Revenue generated through strategic partnerships with pharmaceutical companies for drug discovery, including co-development programs, licensing agreements, and collaborative research arrangements. The company develops internal therapeutic programs while partnering with pharma companies.
- Data Licensing and AI Platform Access: Monetization of the proprietary Nephronomics Atlas database and AI platform through licensing arrangements with pharmaceutical and biotechnology companies for target discovery and patient stratification.
- Precision Medicine Patient Stratification Services: Services enabling pharmaceutical partners to stratify patients by cardio-renal profiles and tailor therapies accordingly, addressing heterogeneity in treatment response.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Nephronomics product offering
Product offeringCore offering
Nephronomics operates a vertically integrated precision medicine platform built around the Nephronomics Atlas, a proprietary clinical and genomics renal disease database containing matched whole genome sequencing and longitudinal medical records from more than 42,000 patients across U.S. dialysis clinics. The platform applies machine learning and computational biology to multi-omics data, unstructured EMR text, and imaging to enable patient stratification, identification of novel genome-phenome associations, and data-driven therapeutic target discovery for cardio-kidney-metabolic and primary renal diseases. The company licenses this platform and collaborates with pharmaceutical partners on co-development programs for next-generation therapeutics.
Product overview
Nephronomics is a precision medicine company that operates as a vertically integrated platform combining a proprietary clinical-genomic database with machine learning capabilities. The core offering consists of the Nephronomics Atlas database—the world's most robust clinical and genomics renal disease database built on the IRB-approved My Reason research program from Fresenius Medical Care—augmented by ML models that analyze multi-omics data, unstructured EMR text, and imaging data. The platform enables pharmaceutical partners to discover and develop next-generation therapeutics through patient stratification, data-driven target discovery, and validation of broader health outcomes for cardio-kidney-metabolic diseases.
Differentiator
Problem solved
Functional benefit
Brands
- Nephronomics Atlas: The world's most robust clinical and genomics renal disease database, consisting of matched whole genome sequencing and longitudinal medical records.
Products and services
- Nephronomics Atlas The Nephronomics Atlas is the world's most robust clinical and genomics renal disease database, consisting of matched whole genome sequencing and longitudinal medical records from U.S. dialysis patients. The database vertically integrates ML and computational biology tools to analyze EMR text, multi-omics data, and imaging data, and is offered to pharmaceutical and biotech partners for cardio-kidney-metabolic drug discovery and patient stratification.
- My Reason Research Program My Reason is an IRB-approved research program sponsored by Fresenius Medical Care that has assembled biospecimens and phenotypic data from more than 35,000 patients. It serves as the foundational patient cohort and data source underwriting the Nephronomics Atlas database.
- Nephronomics Precision Medicine Platform The Nephronomics Precision Medicine Platform vertically integrates the world's most robust cardio-kidney-metabolic disease database of clinical and genomic data with ML models to develop targeted therapies against underlying molecular mechanisms. It enables pharmaceutical partners to discover and develop next-generation therapeutics through patient stratification, data-driven target discovery, and validation of broader health outcomes.
- Precision Medicine Patient Stratification Services Services that integrate Nephronomics' patient data and ML models to stratify patients by cardio-renal profiles and tailor therapies accordingly, addressing heterogeneity in treatment response. Provided to pharmaceutical and biotech partners for clinical trial design and therapeutic development in cardio-kidney-metabolic disease.
Quantifiable outcome
- Single gene mutations may account for at least 30% of non-diabetic kidney disease cases
- +1 more outcomes
Companies that use Nephronomics
Customer profileSegments1 record
Ideal customer profiles1 record
Nephronomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature4 records
Nephronomics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Fresenius Medical CareflagshipNephronomics is a joint venture with Fresenius Medical Care, the global leader in products and services for individuals with renal diseases. Fresenius sponsors the My Reason IRB-approved research program that provides access to patient biospecimens and phenotypic data. This partnership provides exclusive access to the world's largest renal dataset.
- Mechanica PartnerscoreNephronomics was formed as a joint venture between Mechanica Partners and Fresenius Medical Care. Mechanica Partners contributes operational expertise and scientific innovation capabilities to the venture.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
Nephronomics competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Nephronomics social profiles
Digital presenceNephronomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nephronomics leadership team
Management profileNumber of profiles
Profiles6 records
Nephronomics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nephronomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nephronomics
What does Nephronomics do?
Nephronomics operates a vertically integrated precision medicine platform built around the Nephronomics Atlas, a proprietary clinical and genomics renal disease database containing matched whole genome sequencing and longitudinal medical records from more than 42,000 patients across U.S. dialysis clinics. The platform applies machine learning and computational biology to multi-omics data, unstructured EMR text, and imaging to enable patient stratification, identification of novel genome-phenome associations, and data-driven therapeutic target discovery for cardio-kidney-metabolic and primary renal diseases. The company licenses this platform and collaborates with pharmaceutical partners on co-development programs for next-generation therapeutics.
Is Nephronomics a public or private company?
Nephronomics is a private company. It is classified as corporate owned and is currently operating.
When was Nephronomics founded?
Nephronomics was founded in 2023. It employs 1 to 10 people.
Where is Nephronomics based?
Nephronomics is headquartered in Boston, United States, in the North America region.
How does Nephronomics make money?
Three revenue lines are on record. Pharmaceutical Partnerships and Co-development is the primary driver. The others are data Licensing and AI Platform Access and precision Medicine Patient Stratification Services.
Does Nephronomics have an API?
No public API is recorded for Nephronomics.
What industry is Nephronomics in?
Nephronomics's product category is Precision Medicine Platform. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541690 and its SIC code is 8731.